Article
Chicago -- Although published clinical trial results suggest systemic retinoid therapy administered for skin cancer chemoprevention in immunosuppressed organ transplant recipients is well tolerated despite causing frequent adverse events,
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.